GlassScriptPhysician profile
Carlos Pacheco
NPI 1104824127
$31,985.05
in general payments reported to CMS, 2019-2025
54 companies · $2,575 in 2025
The $2,575 reported for 2025 was more than what 81% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $5,674 · 2021: $499 · 2022: $724 · 2023: $2,277 · 2024: $2,025 · 2025: $2,575.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,876.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,876.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $12,037.44 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Tandem Diabetes Care, INC. | $6,111.08 | 2019-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbvie INC. | $3,603.88 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $1,865.41 | 2019-2025 | |
| Lilly USA, LLC | $1,177.72 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $681.93 | 2021-2025 | |
| Amgen INC. | $579.01 | 2019-2025 | Tepezza, Evenity, Prolia |
| Abbott Laboratories | $469.23 | 2019-2025 | Freestyle Libre, Thoratec Heartmate 3 Lvas Implant Kit, Proclaim |
| Beta Bionics, INC. | $453.08 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Ibsa Pharma INC. | $410.43 | 2019-2025 | Tirosint, Licart, Tirosint |
| Radius Health, INC. | $403.67 | 2019-2025 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $374.28 | 2019-2025 | Jardiance, Synjardy |
| Insulet Corporation | $328.57 | 2019-2022 | |
| Cequr Corporation | $328.18 | 2021-2025 | Cequr Simplicity |
| Amneal Pharmaceuticals LLC | $275.62 | 2019-2025 | Unithroid |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos Pacheco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.